Haplo Peripheral Blood Sct In GVHD Prevention

* This is a pilot study in subjects undergoing reduced-intensity haploidentical peripheral blood stem cell transplantation who will receive graft-versus-host disease prevention with post-transplant cyclophosphamide, followed by sirolimus, mycophenolate mofetil, and RGI-2001. * The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * The standard of care drugs of fludarabine, cyclophosphamide, melphalan, radiation, sirolimus, and mycophenolate mofetil are all FDA approved. * Eligible Participants will be placed in 1 of 2 groups, per physicians discretion: * Regimen #1 : * Before stem cell transplant:Fludarabine + Cyclophosphamide + Radiation * After stem cell transplant: Cyclophosphamide + Sirolimus +Mycophenolate mofetil + RGI-2001 * Regimen #2 * Before stem cell transplant: fludarabine + melphalan + radiation * After stem cell transplant: cyclophosphamide + sirolimus +Mycophenolate mofetil + RGI-2001 * A total of 20 participants will be enrolled to this trial * The U.S. Food and Drug Administration (FDA) has not approved RGI-2001 as a treatment for any disease.